Ref. No: Date: Subject: 1953 31/07/25 Oncology MF

REQUEST

Q1. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months)

Myelofibrosis (ICD-10 code: D47.4)

Polycythaemia Vera (ICD-10 code: D45)

Q2. How many patients were initiated on the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months)

- Fedratinib
- Momelotinib

Q3. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

- Hydroxycarbamide
- Interferon therapy

RESPONSE

Q1. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months)

• Myelofibrosis (ICD-10 code: D47.4) 0

Polycythaemia Vera (ICD-10 code: D45) 0

Q2. How many patients were initiated on the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the below treatments in the previous 6 months)

- Fedratinib 0
- Momelotinib <5

Q3. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

- Hydroxycarbamide <5
- Interferon therapy 0